Bladder Ca biomarkers and BCG: New knowledge of the urinary microbiome
Study findings have implications for noninvasive markers to predict the course of UCC
Related Articles
Christina Ching, MD, on predictors of follow-up after pediatric stone surgery
“Interestingly, the patients that were more likely to follow-up were those patients that were seen and established within our urology clinic,” says Christina B. Ching,…
Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC
“Considering that almost all patients in the combined treatment group achieved testosterone recovery at 1 year, the results support that this short term (intermittent) combined…
Expert discusses triplet regimens in metastatic hormone-sensitive prostate cancer
“In terms of how I select patients, I really look at the timing of metastatic disease, so whether it’s metachronous or synchronous and the volume,…
Amy E. Krambeck, MD, on what’s needed to improve safety, efficacy of HoLEP
“I would also like us to be able to reliably use even smaller scopes, but keep them efficient,” says Amy E. Krambeck, MD.
Alicia Morgans, MD, MPH, on PSADT awareness and prostate cancer treatment initiation
“It is important for us to ask patients whether they want to intensify or not, and not make assumptions,” says Alicia Morgans, MD, MPH.
Data refute concerns about telehealth as Congress weighs legislation
“Five years after telehealth suddenly became a routine part of care for most Americans, we show that it has not led to runaway utilization or…
Smaller size, patient control advantages of neurostimulator for OAB
“[The lack of] a battery makes it ultra small. That’s really important,” says Colin Goudelocke, MD.
Investigators highlight real-world data on nadofaragene firadenovec in NMIBC
“At 3 months, those patients had a 79% complete response rate, which was durable in 74% at 6 months and 60% at 9 months,” says…
Dr Louise Kostos discusses combination therapies in mHSPC
“It was a really interesting paper to develop and write, because over the past decade, there’s been such a paradigm shift in the treatment of…
Identifying unique therapeutic targets for chromophobe kidney cancer
“What we hope overall is that this is a biological study that might inform therapeutic development for this disease,” says David A. Braun, MD, PhD.